secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anebulo Pharmaceuticals, Inc. (ANEB)
CIK:        0001815974
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0001493152-24-045133
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anebulo Pharma Q1 net loss narrows to $2.2M; awarded $1.9M NIDA grant for selonabant
--------------------------------------------------------------------------------

- Net loss of $2.2M ($0.08/sh) vs $2.5M ($0.10/sh) in prior year quarter.
- Operating expenses of $2.4M, down from $2.5M year-over-year.
- Cash $1.4M at Sept 30, 2024; access to $10M loan facility.
- Awarded $1.9M NIDA grant to support IV selonabant development.
- Plans to enroll first healthy volunteer in IV study in first half of 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815974/000149315224045133/0001493152-24-045133-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815974/000149315224045133/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-045133

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer